EUVIMEDEUVIMED entdecken
Crossref

Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy

Binglei Zhang, Jianxiang Shi, Xiaojing Shi, Xiaolu Xu, Le Gao, Song Li, Mengmeng Liu, Mengya Gao, Shuiling Jin, Jian Zhou, Dandan Fan, Fang Wang und 7 weitere

Drug Resistance Updates · 2024

DOI: 10.1016/j.drup.2024.101068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2024. Verfasst von Binglei Zhang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China. Hauptthemen laut MEDLINE: Trastuzumab, Breast Neoplasms, Antibodies, Bispecific, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Henan Provincial Science and Technology Research Project, Natural Science Foundation of Henan Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment for trastuzumab-resistant breast cancer (BC) remains a challenge in clinical settings. It was known that CD47 is preferentially upregulated in HER2+ BC cells, which is correlated with drug resistance to trastuzumab. Here, we developed a novel anti-CD47/HER2 bispecific antibody (BsAb) against trastuzumab-resistant BC, named IMM2902. IMM2902 demonstrated high binding affinity, blocking activity, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and internalization degradation effects against both trastuzumab-sensitive and trastuzumab-resistant BC cells in vitro. The in vivo experimental data indicated that IMM2902 was more effective than their respective controls in inhibiting tumor growth in a trastuzumab-sensitive BT474 mouse model, a trastuzumab-resistant HCC1954 mouse model, two trastuzumab-resistant patient-derived xenograft (PDX) mouse models and a cord blood (CB)-humanized HCC1954 mouse model. Through spatial transcriptome assays, multiplex immunofluorescence (mIFC) and in vitro assays, our findings provided evidence that IMM2902 effectively stimulates macrophages to generate C-X-C motif chemokine ligand (CXCL) 9 and CXCL10, thereby facilitating the recruitment of T cells and NK cells to the tumor site. Moreover, IMM2902 demonstrated a high safety profile regarding anemia and non-specific cytokines release. Collectively, our results highlighted a novel therapeutic approach for the treatment of HER2+ BCs and this approach exhibits significant anti-tumor efficacy without causing off-target toxicity in trastuzumab-resistant BC cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrastuzumabBreast NeoplasmsAntibodies, BispecificDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesCD47 AntigenXenograft Model Antitumor AssaysImmunotherapyHumansAnimalsFemaleMiceAntineoplastic Agents, ImmunologicalCell Line, TumorAntibody-Dependent Cell CytotoxicityPhagocytosis

Stichwörter der Autor:innen

Breast cancerCD47/HER2 bispecific antibodyIMM2902MacrophagesTrastuzumab-resistant

Substanzen

TrastuzumabAntibodies, BispecificErb-b2 Receptor Tyrosine KinasesCD47 AntigenAntineoplastic Agents, ImmunologicalERBB2 protein, humanCD47 protein, human

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China.
  • Henan Institute of Medical and Pharmaceutical Sciences, Academy of Medical Science, Zhengzhou University, Zhengzhou, Henan 450052, China.
  • Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450052, China.
  • Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450008, China; Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450052, China.
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc, Shanghai 201203, China.
  • Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China.

Förderung

  • Henan Provincial Science and Technology Research Project
  • Natural Science Foundation of Henan Province
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, B., Shi, J., Shi, X., Xu, X., Gao, L., Li, S., Liu, M., Gao, M., Jin, S., Zhou, J., Fan, D., Wang, F., Ji, Z., Bian, Z., Song, Y., Tian, W., Zheng, Y., Xu, L., & Li, W. (2024). Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2024.101068

Vancouver

Zhang B, Shi J, Shi X, Xu X, Gao L, Li S, et al. Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy. Drug Resistance Updates. 2024. doi:10.1016/j.drup.2024.101068

BibTeX
@article{Zhang2024,
  author = {Zhang, Binglei and Shi, Jianxiang and Shi, Xiaojing and Xu, Xiaolu and Gao, Le and Li, Song and Liu, Mengmeng and Gao, Mengya and Jin, Shuiling and Zhou, Jian and Fan, Dandan and Wang, Fang and Ji, Zhenyu and Bian, Zhilei and Song, Yongping and Tian, Wenzhi and Zheng, Yichao and Xu, Linping and Li, Wei},
  title = {Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy},
  journal = {Drug Resistance Updates},
  year = {2024},
  doi = {10.1016/j.drup.2024.101068}
}
Kostenlos starten →